Wolters Kluwer Research Now Available via Bloomberg Tradebook
inThought™ healthcare data and analytics reaches key investor audience
PHOENIX, Nov. 10, 2011 /PRNewswire/ -- Wolters Kluwer Pharma Solutions, a leading provider of scientific information and analytics, is providing its industry research and analytics to investors through Bloomberg Tradebook's Independent Research Provider (IRP) offering. The distribution is managed by inThought™, Wolters Kluwer Pharma Solutions' research and consulting business, which specializes in forward-looking analyses of pharmaceutical drugs and medical devices.
Led by a team of industry veterans with extensive sell-side research experience, inThought delivers actionable market research reports read by pharmaceutical and healthcare professionals worldwide. The same research, insights and analytics are now available to Bloomberg Tradebook clients as of today.
"We're looking to partner with independent research providers as a means to differentiate Bloomberg Tradebook from other agency brokers," said Ray Tierney, President and CEO of Bloomberg Tradebook. "InThought is known for publishing independent and informed market analysis that Bloomberg Tradebook customers can use to develop smart trading strategies."
Bloomberg Professional service subscribers have been able to access a variety of research materials from Wolters Kluwer Pharma Solutions in the past, including Source® U.S. prescription data and the Adis R&D Insight™ drug pipeline database. Now, Bloomberg Tradebook customers can access these research tools and services plus regular research updates, company pipeline reports, drug and device revenue models, and custom data pulls from the Adis R&D Insight and Source databases that include information such as prescriber specialty, co-pay amount, and insurance rejection rate for U.S. pharmaceutical products. In addition, Bloomberg Tradebook customers can ask the inThought team to answer questions and discuss drug and medical device companies.
"Given the complexities of drug pipeline data involving pharmaceutical manufacturers, insurance companies, doctors, and patients, it is natural for Bloomberg Tradebook customers to seek deeper and actionable insight from the Wolters Kluwer data," said Ben Weintraub, Director of Research, inThought. "We are excited to work with Bloomberg Tradebook to create an end-to-end solution for investors interested in the healthcare sector."
Access to inThought research is available immediately for Bloomberg Tradebook clients with a research trading account at {TBR<GO>}. Information is also available online at the Bloomberg Tradebook website at www.bloombergtradebook.com and the Wolters Kluwer Pharma Solutions homepage at www.wolterskluwerpharma.com.
About Wolters Kluwer Pharma Solutions
Wolters Kluwer Pharma Solutions, Inc. (Phoenix, AZ and Yardley, PA) is a leading provider of information and analytics to the pharmaceutical, biotech, and medical device industries. The company's brands include Adis, Source® and Lippincott Williams & Wilkins. A provider of business intelligence and services, Adis publishes more than 40 peer-reviewed publications in the area of pharmacology and offers the most respected drug and clinical trials databases in the pharma industry. Lippincott Williams & Wilkins (LWW) is a leading international healthcare publisher with nearly 300 periodicals and 1,500 books in more than 100 disciplines. A longstanding provider of market data and healthcare analytics, Source® offers a unique set of comprehensive patient and physician-level prescribing and usage data. For more information, visit www.wolterskluwerpharma.com.
Wolters Kluwer Pharma Solutions is a part of Wolters Kluwer, a market-leading global information services company with 2010 annual revenues of euro 3.6 billion ($4.7 billion).
Contact: Tom Kivett
Kivett & Company Communications
(212) 727-2935
[email protected]
SOURCE Wolters Kluwer Pharma Solutions
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article